Cited by 66Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsRetinoids in leukemia and cellular processes

Absence of the transcription factor CCAAT enhancer binding protein α results in loss of myeloid identity in bcr/abl-induced malignancy

Wagner, Katharina, Zhang, Pu, Rosenbauer, Frank, Drescher, Bettina, Kobayashi, Susumu, Radomska, Hanna S., Kutok, Jeffery L., Gilliland, D. Gary +2 more·2006·Proceedings of the National Academy of Sciences

Abstract

The lineage-determining transcription factor CCAAT enhancer binding protein α (C/EBPα) is required for myeloid differentiation. Decreased function or expression of C/EBPα is often found in human acute myeloid leukemia. However, the precise impact of C/EBPα deficiency on the maturation arrest in leukemogenesis is not well understood. To address this question, we used a murine transplantation model of a bcr/abl-induced myeloproliferative disease. The expression of bcr/abl in C/EBPα pos fetal liver cells led to a chronic myeloid leukemia-like disease. Surprisingly, bcr/abl-expressing C/EBPα −/− fetal liver cells failed to induce a myeloid disease in transplanted mice, but caused a fatal, transplantable erythroleukemia instead. Accordingly, increased expression of the transcription factors SCL and GATA-1 in hematopoietic precursor cells of C/EBPα −/− fetal livers was found. The mechanism for the lineage shift from myeloid to erythroid leukemia was studied in a bcr/abl-positive cell line. Consistent with findings of the transplant model, expression of C/EBPα and GATA-1 was inversely correlated. Id1, an inhibitor of erythroid differentiation, was identified as a critical direct target of C/EBPα. Down-regulation of Id1 by RNA interference impaired C/EBPα-induced granulocytic differentiation. Taken together, our study provides evidence that myeloid lineage identity of malignant hematopoietic progenitor cells requires the residual expression of C/EBPα.

Integrity signals

Registry

Crossref · 10.1073/pnas.0508143103

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CEBPA knockout or mutation is reported to cause a myeloid to erythroid lineage switch with increased expression of GATA1, and GATA1 interacts with and inhibits p53.

    “CEBPA knockout or mutation is reported to cause a myeloid to erythroid lineage switch with increased expression of GATA1 (refs. 29,30) and, in addition, GATA1 interacts with and inhibits p53 (ref. 45).”
  • The CEBPA/GATA1 expression ratio, an important transcription factor balance that affects erythroid versus myeloid differentiation in leukemia, is disrupted by TP53 mutation.

    “These observations suggest that the CEBPA/GATA1 expression ratio, an important transcription factor balance that affects erythroid versus myeloid differentiation in leukemia29,30, is disrupted by TP53 mutation.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wagner, K., Zhang, P., Rosenbauer, F., Drescher, B., Kobayashi, S., Radomska, H. S., Kutok, J. L., Gilliland, D. G., Krauter, J., & Tenen, D. G.
Affiliations
  • Harvard University (US)
  • Medizinische Hochschule Hannover (DE)
  • Departments of Pathology and
  • Brigham and Women's Hospital (US)
Venue
Proceedings of the National Academy of Sciences
Published
2006-04-18
Volume
103
Issue
16
Pages
6338-6343
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2083457546
Cited by
66
References
3
Citations by year
2025: 2 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 1 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 2 · 2013: 5 · 2012: 5
FWCI
4.02
Type
journal article
Language
en
Open access
closed
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
Funders
  • National Cancer Institute (#CA66996, CA88046, P01CA066996, P30CA006516, R01CA088046)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 62064, K01DK062064)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords
C/EBPα, myeloid differentiation, BCR-ABL, chronic myeloid leukemia, erythroleukemia, GATA-1, SCL, Id1, hematopoietic progenitor cells, transcription factors, myeloproliferative neoplasms, granulocytic differentiation
MeSH terms
T-Cell Acute Lymphocytic Leukemia Protein 1, Animals, Cell Differentiation, Leukemia, Erythroblastic, Acute, Hematopoietic Stem Cells, Neoplasm Transplantation, Proto-Oncogene Proteins, Transcription Factors, Transfection, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Up-Regulation, Fusion Proteins, bcr-abl, Myeloid Cells, CCAAT-Enhancer-Binding Protein-alpha, Xenograft Model Antitumor Assays, RNA Interference, GATA1 Transcription Factor, Mice, Basic Helix-Loop-Helix Proteins, Inhibitor of Differentiation Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review